Skip to main content
Causaly logo

Causaly

Updated Mar 24, 2026

How Causaly stacks up in AI Healthcare — funding data, key investors, and more.

🇬🇧United KingdomAcquiredAI Healthcare

Out of 100

🇬🇧

HQ

United Kingdom

🗓

Founded

2018

💰

Raised

$66M

🏷️

Stage

Acquired

👥

Team

1-50

Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text,

Is this your company? Claim it →

Key Facts

  • Causaly has raised a total of $66M in disclosed funding across 5 funding rounds.
  • Causaly was founded in 2018 by Elias Iosif and is headquartered in United Kingdom.
  • Causaly employs approximately 1-50 people.
  • Causaly operates in the AI Healthcare category and is currently at the Acquired stage.
  • Causaly has an Awaira Score of 45/100, ranking it among the tracked AI companies on Awaira.
  • Causaly's most recent funding round was a Series D of $26.4M closed in October 2023.

Source: Awaira · Updated Mar 24, 2026

N/A

Post-money

$66M

All rounds

45/100

2018

1-50 employees

Strengths

Growing team of 1-50 employees

Considerations

!

Valuation not publicly disclosed

Analysis based on publicly available data. Not investment advice.

5

Total Rounds

$13.2M

Avg Round Size

5.4yr

Funding Span

Causaly raised 5 rounds over 5.4 years, averaging $13.2M per round — a pace of roughly one round every 13 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$5M–$20M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Causaly stack up against competitors?

MetricCausalyButterfly NetworkTempusAlan
Awaira Score45/10085/10084/10083/100
Total Raised$66M$370M$1.05B$750M
ValuationN/A$957M$8.1B$5.83B
StageAcquiredPublicPublicSeries D
Founded2018201120152016
Employees1-50500-10002500500-1000
Country🇬🇧🇺🇸🇺🇸🇫🇷
Y

Yiannis Kiachopoulos

Founder & CEO

View founder profile →
StageAcquired
Employees1-50
Country🇬🇧 United Kingdom
Connect
Inactive
5 rounds
Series DLatest

$26.4M

Oct 2023

Series C

$20.46M

Jun 2022

Series B

$11.88M

Feb 2021

Series A

$5.28M

Oct 2019

Seed

$1.98M

Jun 2018

Frequently Asked Questions

What is Causaly's valuation?
Valuation data is currently unavailable. The company may disclose this figure when it announces its next funding round.
Who invested in Causaly?
The investor base hasn't been publicly disclosed. The company may have institutional or angel backers that remain unnamed.
When did Causaly last raise funding?
Capital was most recently raised through a Series D of $26.4M in October 2023.
How many employees does Causaly have?
Around 1-50 people work there, with headquarters in United Kingdom.
What does Causaly do?
Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways. The company operates in the AI Healthcare sector from United Kingdom.
Who founded Causaly?
Behind the company is Elias Iosif, who got it off the ground in 2018 in United Kingdom. Elias Iosif serves as Founder & CEO.
Is Causaly profitable?
Whether the company is profitable hasn't been confirmed publicly. It has raised $66M in total funding and is classified at the Acquired stage.
Where is Causaly headquartered?
Home base is United Kingdom 🇬🇧. The AI Healthcare company was founded in 2018 and operates from there.
⚔️

Compare Causaly

See how Causaly stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →